Sartorius Stedim Biotech posts 9‑month sales of €2.29 bn and 31.3% EBITDA margin, confirms full‑year guidance
Sartorius Stedim Biotech reported 9‑month 2026 sales of €2.289 bn, up 6.5% year‑on‑year, with underlying EBITDA of €716 m and a margin of 31.3%. Net profit rose 26.7% to €277 m and free cash flow increased 58.5% to €264 m. The company reaffirmed its full‑year outlook, expecting operational sales growth of 6‑10% and an EBITDA margin slightly above 31%.
Why it matters
The company’s confirmation of guidance signals that the strong operating performance is expected to continue, supporting cash‑flow generation and balance‑sheet strength for investors. The higher free‑cash‑flow and improved net‑debt‑to‑EBITDA ratio enhance financial flexibility, according to the earnings‑call commentary.
Key facts
- 19‑month 2026 sales were €2.289 bn, a 6.5% increase year‑on‑year. tradingview.com
- 2Underlying EBITDA for the period was €716 m, up 4.8% year‑on‑year. finanznachrichten.de
- 3EBITDA margin was 31.3%. finanznachrichten.de
- 4Net profit amounted to €277 m, a 26.7% increase. finanznachrichten.de
- 5Free cash flow rose 58.5% to €264 m. finance.yahoo.com
- 6Net‑debt‑to‑EBITDA improved to 2.26 times. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.